Microbot Medical® to Leverage Current Users Experience of the LIBERTY® Endovascular Robotic System at Key Oncology Conference to Support Commercial Adoption

Core Insights - Microbot Medical Inc. is participating in the Society of Interventional Oncology (SIO) annual meeting to share insights and experiences regarding its LIBERTY Endovascular Robotic System, which is currently in a limited market release phase [1][2] - The LIBERTY System is the first FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enhance precision and reduce radiation exposure [3][4] - The company aims to accelerate commercial awareness and adoption of the LIBERTY System through direct engagement with interventional oncologists at the conference [1][2] Company Overview - Microbot Medical Inc. focuses on transforming endovascular procedures with advanced robotic technology, highlighted by the LIBERTY Endovascular Robotic System [4] - The company has a strong intellectual property portfolio and is committed to innovation in the medical device sector [4] Market Context - The interventional oncology market is described as a large and expanding multi-billion dollar sector, with increasing procedure volumes driving demand for advanced technologies like LIBERTY [2] - The full market release of the LIBERTY System is planned for April 2026, coinciding with the Society of Interventional Radiology (SIR) conference [3]